Tags

Type your tag names separated by a space and hit enter

Desogestrel, norgestimate, and gestodene: the newer progestins.
Ann Pharmacother. 1995 Jul-Aug; 29(7-8):736-42.AP

Abstract

OBJECTIVE

To review and compare the newer progestins desogestrel, norgestimate, and gestodene with regard to chemistry, pharmacokinetics, efficacy, and tolerability.

DATA SOURCES

Primary literature on desogestrel, norgestimate, and gestodene was identified from a comprehensive MEDLINE English-literature search from 1984 through 1994, with additional studies selected by review of the references. Indexing terms included progestins, desogestrel, gestodene, norgestimate, levonorgestrel, and norgestrel.

STUDY SELECTION

Only human clinical and pharmacokinetic trials performed in Europe, Canada, and the US were included.

DATA EXTRACTION

All available data from human studies were reviewed; both comparative and noncomparative studies were included because of the paucity of direct comparative information available.

DATA SYNTHESIS

The newer progestins were designed to minimize the adverse effects (e.g., acne, hirsuitism, nausea, carbohydrate and lipid metabolism changes) observed with older oral contraceptives (OCs) while maintaining efficacy and good menstrual cycle control. Desogestrel, norgestimate, and gestodene have minimal amounts of androgenicity and antiestrogenic potential. All of these agents are pharmacokinetically similar to older agents: they are highly bioavailable when administered orally, hepatically metabolized, and obtain steady-state concentrations after 8-10 days of continuous administration. The newer agents have similar Pearl Indexes and slightly better cycle control. Furthermore, the new progestins appear to cause fewer adverse effects, such as acne and hirsuitism, and similar rates of weight gain, blood pressure changes, and lipid and carbohydrate metabolism changes.

CONCLUSIONS

Desogestrel, norgestimate, and gestodene appear to offer clinical advantages because of their decreased androgenicity. Women whose cycles are currently well controlled with other OCs should not be switched to a newer progestin. However, any of the combination OC products that contain these progestins may be prescribed for women intolerant of older agents or to first-time users of OCs. The newer progestins appear to be efficacious and offer similar cycle control, improved safety and tolerability profiles, and comparable price with the older agents.

Authors+Show Affiliations

School of Medicine, West Virginia University, Robert C Byrd Health Sciences Center, Charleston 25304, USA.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

8520092

Citation

Kaplan, B. "Desogestrel, Norgestimate, and Gestodene: the Newer Progestins." The Annals of Pharmacotherapy, vol. 29, no. 7-8, 1995, pp. 736-42.
Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother. 1995;29(7-8):736-42.
Kaplan, B. (1995). Desogestrel, norgestimate, and gestodene: the newer progestins. The Annals of Pharmacotherapy, 29(7-8), 736-42.
Kaplan B. Desogestrel, Norgestimate, and Gestodene: the Newer Progestins. Ann Pharmacother. 1995 Jul-Aug;29(7-8):736-42. PubMed PMID: 8520092.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Desogestrel, norgestimate, and gestodene: the newer progestins. A1 - Kaplan,B, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez KW - Acne KW - Americas KW - Biology KW - Blood Pressure KW - Body Weight KW - Canada KW - Contraception KW - Contraceptive Agents, Female--beneficial effects KW - Contraceptive Agents, Female--pharmacodynamics KW - Contraceptive Agents, Female--side effects KW - Contraceptive Agents, Progestin--beneficial effects KW - Contraceptive Agents, Progestin--pharmacodynamics KW - Contraceptive Agents, Progestin--side effects KW - Contraceptive Agents--beneficial effects KW - Contraceptive Agents--pharmacodynamics KW - Contraceptive Agents--side effects KW - Contraceptive Effectiveness KW - Dermatitis KW - Desogestrel--pharmacodynamics KW - Desogestrel--side effects KW - Developed Countries KW - Diseases KW - Europe KW - Family Planning KW - Gestodene--pharmacodynamics KW - Gestodene--side effects KW - Hemic System KW - Hirsutism KW - Levonorgestrel--pharmacodynamics KW - Levonorgestrel--side effects KW - Literature Review KW - Norgestimate--pharmacodynamics KW - Norgestimate--side effects KW - Norgestrel--pharmacodynamics KW - Norgestrel--side effects KW - North America KW - Northern America KW - Physiology KW - Progestins, Low-dose--beneficial effects KW - Progestins, Low-dose--side effects KW - Signs And Symptoms KW - United States SP - 736 EP - 42 JF - The Annals of pharmacotherapy JO - Ann Pharmacother VL - 29 IS - 7-8 N2 - OBJECTIVE: To review and compare the newer progestins desogestrel, norgestimate, and gestodene with regard to chemistry, pharmacokinetics, efficacy, and tolerability. DATA SOURCES: Primary literature on desogestrel, norgestimate, and gestodene was identified from a comprehensive MEDLINE English-literature search from 1984 through 1994, with additional studies selected by review of the references. Indexing terms included progestins, desogestrel, gestodene, norgestimate, levonorgestrel, and norgestrel. STUDY SELECTION: Only human clinical and pharmacokinetic trials performed in Europe, Canada, and the US were included. DATA EXTRACTION: All available data from human studies were reviewed; both comparative and noncomparative studies were included because of the paucity of direct comparative information available. DATA SYNTHESIS: The newer progestins were designed to minimize the adverse effects (e.g., acne, hirsuitism, nausea, carbohydrate and lipid metabolism changes) observed with older oral contraceptives (OCs) while maintaining efficacy and good menstrual cycle control. Desogestrel, norgestimate, and gestodene have minimal amounts of androgenicity and antiestrogenic potential. All of these agents are pharmacokinetically similar to older agents: they are highly bioavailable when administered orally, hepatically metabolized, and obtain steady-state concentrations after 8-10 days of continuous administration. The newer agents have similar Pearl Indexes and slightly better cycle control. Furthermore, the new progestins appear to cause fewer adverse effects, such as acne and hirsuitism, and similar rates of weight gain, blood pressure changes, and lipid and carbohydrate metabolism changes. CONCLUSIONS: Desogestrel, norgestimate, and gestodene appear to offer clinical advantages because of their decreased androgenicity. Women whose cycles are currently well controlled with other OCs should not be switched to a newer progestin. However, any of the combination OC products that contain these progestins may be prescribed for women intolerant of older agents or to first-time users of OCs. The newer progestins appear to be efficacious and offer similar cycle control, improved safety and tolerability profiles, and comparable price with the older agents. SN - 1060-0280 UR - https://www.unboundmedicine.com/medline/citation/8520092/Desogestrel_norgestimate_and_gestodene:_the_newer_progestins_ L2 - https://journals.sagepub.com/doi/10.1177/106002809502907-817?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -